12/5/2022 1:04:25 AM
Valneva Reports Positive 12-Month Antibody Persistence Data For Single-Shot Chikungunya Vaccine Candidate
12/1/2022 1:07:13 AM
Valneva, Pfizer Report 6-Month Antibody Persistence Data In Children And Adults For Lyme Disease Vaccine Candidate
11/17/2022 1:17:15 AM
Valneva Appoints Dipal Patel As Chief Commercial Officer
9/30/2022 1:20:03 AM
Valneva Announces Pricing Of EUR 102.9 Mln Global Offering Of American Depositary Shares And Ordinary Shares
9/26/2022 1:13:17 AM
Valneva Provides Further Update On COVID-19 Activities
9/8/2022 1:04:35 AM
Valneva And VBI Vaccines Announce European Partnership For Marketing And Distribution Of PreHevbri
8/29/2022 6:53:57 AM
Valneva Reports Further Positive Phase 3 Results For Adjuvanted COVID-19 Vaccine VLA2001
8/8/2022 4:53:37 PM
Pfizer And Valneva Initiate Phase 3 Study Of Lyme Disease Vaccine Candidate
6/24/2022 1:26:58 AM
Valneva Announces Appointment Of Two New Supervisory Board Members